Heteroaryl inhibitors of plasma kallikrein
JP2024516073A5Pending Publication Date: 2025-03-25TAKEDA PHARMA CO LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2023557140
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-03-17
- Filing Date
- 2022-03-16
- Publication Date
- 2025-03-25
AI Technical Summary
Technical Problem
Hereditary angioedema (HAE) is caused by deficient or dysfunctional C1 inhibitor levels, leading to excessive bradykinin production and debilitating swelling attacks, with high mortality rates if untreated.
Method used
Development of compounds that bind to plasma kallikrein to inhibit its activity, potentially treating HAE and other plasma kallikrein-mediated diseases.
Benefits of technology
The compounds effectively inhibit plasma kallikrein, offering therapeutic benefits for treating HAE and diabetic macular edema with suitable bioavailability and half-life.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides compounds and compositions thereof that are useful as inhibitors of plasma kallikrein and that exhibit desirable properties therefor.
Need to check novelty before this filing date? Find Prior Art